Press Release - Company Data

Protox Therapeutics Changes Name to Sophiris Bio
Posted 2012-04-02 01:19NAI Editing
announced that it has changed its name to Sophiris Bio, Inc. effective today, and the symbol "SHS" has been reserved for its use on the Toronto Stock Exchange.

Protox Therapeutics Announces Closing of Additional CDN $8.3M Investment by Warburg Pincus
Posted 2012-03-29 01:18NAI Editing
, a developer of innovative products for the treatment of urological diseases, announced that on March 28, 2012 it closed the previously announced additional investment of CDN $8.3 million by Warburg

Protox Therapeutics Announces Additional CDN $8.3M Investment by Warburg Pincus
Posted 2012-03-28 01:10NAI Editing
, a developer of innovative products for the treatment of urological diseases, today announced that Warburg Pincus has agreed to invest an additional CDN $8.3 million in Protox, pursuant to its rights

Protox Completes Dosing of Final Cohort of Patients in Transrectal Study
Posted 2012-03-28 01:09NAI Editing
, a developer of innovative products for the treatment of urological diseases, today announced that it has completed dosing of all four cohorts of patients in its previously announced transrectal stud

Protox Reports Fourth Quarter and Full Year 2011 Financial Results and Achievements
Posted 2012-03-21 01:03NAI Editing
, a developer of innovative products for the treatment of urological diseases, today announced financial results and achievements for the Fourth Quarter and year ended December 31, 2011.

Protox Therapeutics Announces Additional CDN $8.3M Investment By Warburg Pincus
Posted 2011-12-23 00:32NAI Editing
, a developer of innovative products for the treatment of urological diseases, today announced that Warburg Pincus has agreed to invest an additional CDN $8.3M in Protox, pursuant to its rights under

Protox Completes Dosing of Second Cohort of Patients in Transrectal Study
Posted 2011-12-22 01:21NAI Editing
, a developer of innovative products for the treatment of urological diseases, today announced that it has completed dosing of the second cohort of patients in its previously announced transrectal stu

Protox Therapeutics Appoints Richard Yocum as Chief Medical Officer
Posted 2011-12-12 00:43NAI Editing
, a developer of innovative products for the treatment of urological diseases, today announced the appointment of Dr. Richard Yocum as Chief Medical Officer, located in San Diego.

Protox Reports Third Quarter 2011 Financial Results and Achievements
Posted 2011-11-14 03:12NAI Editing
, a developer of innovative products for the treatment of urological diseases, today announced financial results and achievements for the Quarter ended September 30, 2011.

Protox Announces the Dosing of Patients in Transrectal Study
Posted 2011-10-20 00:05NAI Editing
, a developer of innovative products for the treatment of urological diseases, today announced that it has completed dosing of the first cohort of patients in its transrectal study of PRX302 for the t